RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Most under valued or just a p.o.s. stock?Biggainer wrote: gojotv, I love your enthusiasm. TLT should be trading in the dollar range, but for some reason, it's having a hard time getting there. I see so many biotech stocks in it's preclinical stage and is worth multiple of what Theralase market cap is. I just don't understand how they value these biotech companies. They have the potential to cure certain kinds of cancers.
Think about it, out of the 9 patients that have been treated, after 180 days, only 1 had no response, while 4 have complete response, while the 2 others have partial response and the remaining 2i s to be determined.
That's why i think this stock is tremendously undervalued, or is a P.O.S. stock. i really think it should be trading at around $2 a share, but then again, we don't know why the price is being surpressed
(My conspiracy theory) - I don't want to think this way but I sometimes think that it's done on purpose, because they have a real thing here, and maybe they don't want it to suceed. Because a cure for cancer means billions and billions of lost revenue for the big pharma.
Yep...those response rates were encouraging, & the one that had no response (that is, stable or unchanged CIS disease) could become a CR with the 2nd treatment....just as the partial responders have a chance to become, & the TBDs (if they show stable disease or better). Excited to see data on patients who will have received "two optimized" treatments. The P.O.S. stock will feel like a (P)lethora (O)f (S)ilver stock ; ).